Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

Phibro Animal Health is focusing on new developments along with incremental registrations and growing volumes of existing ...

CYBR's focus on identity security, strategic acquisitions and growing ARR base offer strong long-term growth prospects.

RheumaGen raises $15M Series A for HLA gene editing in autoimmune diseases, while RyboDyn gets $4M pre-seed to study non-coding DNA for cancer immunotherapies ...